Description
Product details
CJC-1295 + Ipamorelin — Dual-Pathway GH Secretagogue Blend
This research blend combines two complementary growth hormone secretagogues in a single vial: CJC-1295 (no DAC), a GHRH analog that acts on the pituitary somatotroph, and Ipamorelin, a selective ghrelin-receptor agonist. The pairing engages both pathways that govern natural GH pulse amplitude, which is why dual-agonist blends dominate preclinical research on endogenous GH release.
Mechanism of Action
CJC-1295 binds the GHRH receptor (GHRHR) on anterior pituitary somatotrophs and triggers Gs-protein–mediated cAMP elevation, driving GH synthesis and release. Ipamorelin, a pentapeptide GHRP, binds the growth hormone secretagogue receptor (GHS-R1a), activating phospholipase C and intracellular calcium signaling. Co-administration produces a synergistic GH pulse that exceeds either compound alone in animal models, while Ipamorelin’s receptor selectivity avoids meaningful prolactin, cortisol, or ACTH elevation — a key reason it is studied alongside CJC-1295 rather than older, less-selective GHRPs.
Research Applications
- Endogenous GH pulse and IGF-1 axis studies
- GHRH/GHS-R synergy research
- Lean mass preservation and somatic adaptation models
- Sleep architecture and slow-wave sleep investigations
- Recovery and musculoskeletal adaptation research
- Age-related somatopause modeling
Product Specifications
- Quantity: 5mg CJC-1295 (no DAC) + 5mg Ipamorelin per vial
- Purity: ≥99% each component (HPLC verified)
- Form: Lyophilized powder (co-formulated)
- Storage: Refrigerate after reconstitution
- Testing: Third-party lab tested, COA available on Portal
- Actual Tested Value: 11.26 mg
For research purposes only. Not for human or veterinary use.
